SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+4.52%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$802M
AUM Growth
+$802M
(+21%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
19.72%
Top 10 Holdings %
Top 10 Hldgs %
99.69%
Holding
13
New
2
Increased
7
Reduced
–
Closed
–
Top Buys
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$34.8M |
| 2 |
AGN
Allergan plc
AGN
|
$29.2M |
| 3 |
Biogen
BIIB
|
$27.7M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$23.8M |
| 5 |
MDCO
Medicines Co
MDCO
|
$20.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 80.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $175M | 21.76% | 1,042,500 +174,500 | +20% | +$29.2M |
|
|
MDCO
2
DELISTED
Medicines Co
MDCO
| $153M | 19.1% | 4,202,000 +566,000 | +16% | +$20.6M |
|
|
3
Biogen
BIIB
$19.4B
| $150M | 18.75% | 643,000 +118,342 | +23% | +$27.7M |
|
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $106M | 13.25% | 9,718,000 +2,175,800 | +29% | +$23.8M |
|
5
Innoviva
INVA
$1.29B
| $90.9M | 11.33% | 6,242,000 +215,900 | +4% | +$3.14M |
|
|
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $60.2M | 7.51% | 757,000 +437,000 | +137% | +$34.8M |
|
7
Jazz Pharmaceuticals
JAZZ
$7.75B
| $28M | 3.49% | 196,500 +96,500 | +97% | +$13.8M |
|
8
Puma Biotechnology
PBYI
$254M
| $18M | 2.25% | 1,417,000 | – | – |
|
9
Mersana Therapeutics
MRSN
$36.5M
| $15.2M | 1.89% | 3,750,000 | – | – |
|
10
Cyclerion Therapeutics
CYCN
$7.91M
| $2.86M | 0.36% | +250,000 | New | +$2.86M |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $2.31M | 0.29% | +1,851,851 | New | +$2.31M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $103K | 0.01% | 1,000 | – | – |
|
13
AbbVie
ABBV
$372B
| $72K | 0.01% | 1,000 | – | – |
|